| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.22 | 0.003 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.003 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.14 | 0.004 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.096 | 0.004 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.11 | 0.006 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.006 |